Blood test measuring alpha‑synuclein clumping to detect neurodegenerative conditions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational project based at Xuanwu Hospital that measures alpha‑synuclein aggregation seeding activity in plasma using RT‑QuIC–style assays. Researchers will enroll patients diagnosed or likely to have Parkinson's disease and related synucleinopathies under the 2015 MDS diagnostic criteria and collect clinical information alongside blood samples. The goal is to compare plasma seeding activity patterns across clinical groups to find signals that distinguish different synucleinopathies. The work aims to build a clinical database and correlate blood assay results with clinical features to develop a less invasive diagnostic biomarker.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- Grouping criteria for PD patients: All PD patients who join the group need to meet the following conditions at the same time: The diagnosis of primary PD patients is based on the 2015 International Association for Movement Disorders (MDS) Parkinson's disease diagnosis standard, and all patients need to meet the clinical diagnosis or likely Parkinson's disease diagnosis criteria. Quasi; All patients come from the outpatient clinic of Xuanwu Hospital Affiliated to Capital Medical University, and the clinical evaluation and disease diagnosis are completed by a movement disorder specialist. This project is approved by the Ethics Committee of Xuanwu Hospital Affiliated to Capital Medical University. The subjects who participated in the study signed the informed consent form. Fully improve the information of PD patients and form an NSFC 2024 clinical information database. Establish an evaluation scale based on various indicators such as basic demographic data, general disease status and past history and exercise symptom evaluation, including Hoehn \& Yahr staging, unified Parkinson's disease assessment scale (MDS- UPDRS), concise mental state examination (MMSE) examination, Monte Lear scale (MOCA), rapid eye movement sleep behavior disorder Hong Kong questionnaire (RBDQ-HK), Hamilton depression scale (HAMD) and anxiety scale (HAMA), integrating a number of sports and non-sports indicators, comprehensively considering and evaluating the patient's condition, for the follow-up relevant Sexual analysis provides accurate and complete clinical information.MSA patients need to meet the MSA clinical diagnosis criteria updated in 2008 by the Europe Multiple System Atrophy Study Group (EMSA-SG). For DLB patients, use the 2017 standard for diagnosis and grouping.

Exclusion Criteria:

* Patients with Parkinson's syndrome but not primary PD, patients with brain surgery/deep brain electrode stimulation, or patients diagnosed with dementia according to the Diagnostic and Statistical Manual of Mental Illness formulated by the American Association of Mental Illness. PD patients with mild cognitive dysfunction are not excluded.

Where it's running

• Xuanwu Hospital
  Beijing, Beijing Municipality, China Recruiting
• Xuanwu Hospital
  Beijing, Beijing Municipality, China Completed

Study contacts

• Study coordinator: Weiwei YANG, Ph.D.
• Email: yangww_2010@163.com
• Phone: +86 010-83198271

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acoustic Stimulation During Sleep for Alzheimer’s Disease

  Researchers test whether playing gentle sounds during sleep can help people with Alzheimer’s disease see if their thinking improves compared with a sham sound.

  Recruiting Xuanwu Hospital, Beijing · Beijing · NCT07924657

• See if multimodal biomarkers can map changes from mild cognitive impairment to dementia

  This observational study tests whether clinical, blood, and brain-imaging markers can tell apart stages of cognitive decline and predict progression from mild cognitive impairment to dementia in about 600 people.

  Recruiting Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT07876570

• Satralizumab in the early treatment of NMOSD attacks: a multicenter real-world study

  This study tests whether starting Satralizumab during an NMOSD attack is safe and helpful for adults with AQP4-IgG–positive NMOSD.

  Recruiting Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT07762872

• Real-World Experience With the WEB Device for Intracranial Aneurysms

  This study tests how well the Woven EndoBridge device works in routine treatment of intracranial aneurysms in China across multiple centers.

  Recruiting Xuanwu Hospital, Beijing · Beijing · NCT07620626

• Multicenter Registry of Intracranial Dural Arteriovenous Fistulas in China

  This study will collect and analyze data from many hospitals in China to see how common intracranial dural AV fistulas are, how they’re treated, and what outcomes look like for patients.

  Recruiting Xuanwu Hospital, Beijing · Beijing · NCT07604688

• Preventive Analgesia With Anrikefon in Laparoscopic Gallbladder Surgery

  This study tests whether giving Anrikefon before or during laparoscopic cholecystectomy can reduce early postoperative pain.

  Recruiting Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT07566663

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.